Entecavir Patent Expiration

Entecavir was first introduced by Bristol Myers Squibb in its drug Baraclude on Mar 29, 2005. 18 different companies have introduced drugs containing Entecavir.


Entecavir Patents

Given below is the list of patents protecting Entecavir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Baraclude US5206244

(Pediatric)

Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines Aug 21, 2015

(Expired)

Bristol Myers Squibb
Baraclude US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines Feb 21, 2015

(Expired)

Bristol Myers Squibb



Entecavir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Entecavir Generic API Manufacturers

Several generic applications have been filed for Entecavir. The first generic version for Entecavir was by Teva Pharmaceuticals Usa and was approved on Aug 26, 2014. And the latest generic version is by Conba Usa Inc and was approved on Dec 23, 2024.

Given below is the list of companies who have filed for Entecavir generic, along with the locations of their manufacturing plants worldwide.